Amgen Inc (BUE:AMGN)
ARS 10400 250 (2.46%) Market Cap: 151.64 Til Enterprise Value: 203.40 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 57/100

Amgen Inc Investor Conference Call from American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting Transcript

Feb 26, 2021 / 06:00PM GMT
Release Date Price: ARS3317.5 (-1.22%)
Operator

My name is Erica, and I will be your conference facilitator today for Amgen's conference call from the American Academy of Allergy, Asthma & Immunology Annual Meeting. (Operator Instructions) I will now introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may begin.

Arvind Sood
Amgen Inc. - VP of IR

Thank you, Erica. Good morning, and good afternoon, everybody. Thanks for joining us. So earlier this morning, we presented important data in a poster forum on tezepelumab, and this was presented at the American Academy of Asthma, Allergy and Immunology Meeting. This data is from our Phase III NAVIGATOR study evaluating tezepelumab in severe asthma patients.

To review this data in additional detail, I'm joined this morning by Dr. David Reese, our Executive Vice President of Research and Development; as well as 2 of our clinical investigators who Dave will introduce and who can provide a broader perspective on how they see tezepelumab fitting within the armamentarium of therapies to treat severe asthmatic patients. Dave will make a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot